Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Mereo Biopharma Group Plc's Business Segments
Mereo Biopharma Group Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Member
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 1 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | $ 1 | - |
Description of Mereo Biopharma Group Plc
Mereo Biopharma Group Plc is a UK-based clinical-stage biopharmaceutical company that focuses on developing innovative therapeutics for rare and specialty diseases. The company is dedicated to developing therapies that have the potential to transform the lives of patients affected by diseases that currently have limited or no treatment options. Mereo Biopharma aims at commercializing these therapies through partnerships or in-house efforts.
Mereo Biopharma has a diversified pipeline of clinical-stage product candidates that range from rare metabolic disorders to oncology. The company's lead program is setrusumab, which is in Phase 3 development for osteogenesis imperfecta, a rare genetic bone disorder. The company also has an active clinical program in the treatment of Alport syndrome, a rare genetic kidney disease. Additionally, the company is developing navicixizumab, which is in Phase 1b/2a development for the treatment of cancers with high unmet medical needs, such as pancreatic and ovarian cancers.
Mereo Biopharma has a strong track record of partnering with leading pharmaceutical companies to advance its pipeline programs to commercialization. The company has formed collaborations with Novartis, Oncomed, and Ultragenyx Pharmaceutical, among others.
Mereo Biopharma was founded in 2015 and is headquartered in London, UK, with offices in the US and Europe. The company has a dedicated team of experienced professionals who have extensive expertise in drug development and commercialization. Mereo Biopharma has a market capitalization of approximately £45 million as of June 202
In summary, Mereo Biopharma is a clinical-stage biopharmaceutical company that aims to address unmet medical needs by developing innovative therapies for rare and specialty diseases. The company has a diversified pipeline of clinical-stage product candidates, a successful partnering strategy, and a talented team of professionals dedicated to transforming the lives of patients through cutting-edge therapeutics.
Mereo Biopharma has a diversified pipeline of clinical-stage product candidates that range from rare metabolic disorders to oncology. The company's lead program is setrusumab, which is in Phase 3 development for osteogenesis imperfecta, a rare genetic bone disorder. The company also has an active clinical program in the treatment of Alport syndrome, a rare genetic kidney disease. Additionally, the company is developing navicixizumab, which is in Phase 1b/2a development for the treatment of cancers with high unmet medical needs, such as pancreatic and ovarian cancers.
Mereo Biopharma has a strong track record of partnering with leading pharmaceutical companies to advance its pipeline programs to commercialization. The company has formed collaborations with Novartis, Oncomed, and Ultragenyx Pharmaceutical, among others.
Mereo Biopharma was founded in 2015 and is headquartered in London, UK, with offices in the US and Europe. The company has a dedicated team of experienced professionals who have extensive expertise in drug development and commercialization. Mereo Biopharma has a market capitalization of approximately £45 million as of June 202
In summary, Mereo Biopharma is a clinical-stage biopharmaceutical company that aims to address unmet medical needs by developing innovative therapies for rare and specialty diseases. The company has a diversified pipeline of clinical-stage product candidates, a successful partnering strategy, and a talented team of professionals dedicated to transforming the lives of patients through cutting-edge therapeutics.
Mereo Biopharma Group Plc is a biopharmaceutical company focused on the development of innovative therapies designed to address significant unmet medical needs, particularly in the realm of rare diseases and oncology. Here is an extensive overview of the segments, products, and services offered by the company.
Segments:
1. Rare Diseases
Mereo Biopharma places a strong emphasis on developing therapies for rare diseases, which are typically defined as conditions that impact a small number of individuals. Generally, a disease is classified as rare if it affects fewer than 200,000 people in the United States. The focus on rare diseases is significant due to the often limited treatment options available for these conditions. Some examples include:
- Osteogenesis Imperfecta (OI): A genetic disorder characterized by fragile bones that break easily.
- Alpha-1 Antitrypsin Deficiency (AATD): A genetic condition that can lead to lung and liver diseases.
- Other associated rare genetic disorders that demand targeted therapeutic approaches.
2. Oncology
In addition to its focus on rare diseases, Mereo Biopharma is involved in oncology, working on innovative therapies to address various cancers. This segment reflects the companys commitment to addressing serious health threats that significantly impact patients’ lives.
Products:
1. Setrusumab
Setrusumab is Mereo Biopharmas flagship drug candidate and represents a significant advancement in the treatment of osteogenesis imperfecta. This anti-sclerostin antibody is designed to enhance bone density and strength, tackling the core issue of brittleness prevalent in OI patients. It has successfully completed a Phase 2b clinical study that provided evidence of its efficacy, showing a statistically significant increase in bone mineral density among adult patients with OI. The focus on this drug highlights an effort to improve the quality of life for individuals suffering from this debilitating condition.
2. Alvelestat
Alvelestat is another key product in Mereo Biopharmas portfolio, designed as an oral leukotriene A4 hydrolase (LTA4H) inhibitor for the treatment of alpha-1 antitrypsin deficiency. Alvelestat has undergone multiple Phase 2 clinical trials and has shown promising results, including a statistically significant reduction in neutrophil elastase activity, which plays a role in lung inflammation and damage. By addressing the underlying pathology of AATD, Alvelestat aims to mitigate the adverse health effects associated with this genetic disorder.
Services:
1. Clinical Development
Mereo Biopharma actively conducts clinical trials to assess the safety and effectiveness of its therapeutic candidates. These trials are crucial for evaluating the potential benefits and risks associated with new treatments, and they are conducted in accordance with regulatory standards to ensure data integrity and patient safety.
2. Regulatory Affairs
Navigating the complex landscape of regulatory requirements is vital for any biopharmaceutical company. Mereo Biopharma engages with various regulatory authorities worldwide to facilitate the approval process for its drug candidates. This includes preparing regulatory submissions, responding to agency queries, and ensuring compliance with local and international regulations.
3. Manufacturing
To meet the demand for high-quality therapeutic products, Mereo Biopharma collaborates with contract manufacturing organizations (CMOs). These partnerships ensure that the companys drug candidates are manufactured in compliance with current Good Manufacturing Practice (cGMP) standards, adhering to stringent quality control measures throughout the production process.
4. Licensing and Collaborations
Mereo Biopharma actively seeks collaborative opportunities with other biopharmaceutical companies. These collaborations are aimed at leveraging synergies in research, development, and commercialization of its drug candidates. The company may also license its proprietary technologies to other entities, allowing for a broader distribution and development framework while generating revenue through royalties.
In summary, Mereo Biopharma Group Plc is deeply engaged in the biopharmaceutical landscape with a robust focus on rare diseases and oncology. The company’s lead products, Setrusumab and Alvelestat, represent significant advancements in their respective areas. Through its comprehensive approach to clinical development, regulatory strategy, manufacturing, and collaborations, Mereo Biopharma reinforces its commitment to addressing critical healthcare challenges faced by patients with debilitating conditions.
Segments:
1. Rare Diseases
Mereo Biopharma places a strong emphasis on developing therapies for rare diseases, which are typically defined as conditions that impact a small number of individuals. Generally, a disease is classified as rare if it affects fewer than 200,000 people in the United States. The focus on rare diseases is significant due to the often limited treatment options available for these conditions. Some examples include:
- Osteogenesis Imperfecta (OI): A genetic disorder characterized by fragile bones that break easily.
- Alpha-1 Antitrypsin Deficiency (AATD): A genetic condition that can lead to lung and liver diseases.
- Other associated rare genetic disorders that demand targeted therapeutic approaches.
2. Oncology
In addition to its focus on rare diseases, Mereo Biopharma is involved in oncology, working on innovative therapies to address various cancers. This segment reflects the companys commitment to addressing serious health threats that significantly impact patients’ lives.
Products:
1. Setrusumab
Setrusumab is Mereo Biopharmas flagship drug candidate and represents a significant advancement in the treatment of osteogenesis imperfecta. This anti-sclerostin antibody is designed to enhance bone density and strength, tackling the core issue of brittleness prevalent in OI patients. It has successfully completed a Phase 2b clinical study that provided evidence of its efficacy, showing a statistically significant increase in bone mineral density among adult patients with OI. The focus on this drug highlights an effort to improve the quality of life for individuals suffering from this debilitating condition.
2. Alvelestat
Alvelestat is another key product in Mereo Biopharmas portfolio, designed as an oral leukotriene A4 hydrolase (LTA4H) inhibitor for the treatment of alpha-1 antitrypsin deficiency. Alvelestat has undergone multiple Phase 2 clinical trials and has shown promising results, including a statistically significant reduction in neutrophil elastase activity, which plays a role in lung inflammation and damage. By addressing the underlying pathology of AATD, Alvelestat aims to mitigate the adverse health effects associated with this genetic disorder.
Services:
1. Clinical Development
Mereo Biopharma actively conducts clinical trials to assess the safety and effectiveness of its therapeutic candidates. These trials are crucial for evaluating the potential benefits and risks associated with new treatments, and they are conducted in accordance with regulatory standards to ensure data integrity and patient safety.
2. Regulatory Affairs
Navigating the complex landscape of regulatory requirements is vital for any biopharmaceutical company. Mereo Biopharma engages with various regulatory authorities worldwide to facilitate the approval process for its drug candidates. This includes preparing regulatory submissions, responding to agency queries, and ensuring compliance with local and international regulations.
3. Manufacturing
To meet the demand for high-quality therapeutic products, Mereo Biopharma collaborates with contract manufacturing organizations (CMOs). These partnerships ensure that the companys drug candidates are manufactured in compliance with current Good Manufacturing Practice (cGMP) standards, adhering to stringent quality control measures throughout the production process.
4. Licensing and Collaborations
Mereo Biopharma actively seeks collaborative opportunities with other biopharmaceutical companies. These collaborations are aimed at leveraging synergies in research, development, and commercialization of its drug candidates. The company may also license its proprietary technologies to other entities, allowing for a broader distribution and development framework while generating revenue through royalties.
In summary, Mereo Biopharma Group Plc is deeply engaged in the biopharmaceutical landscape with a robust focus on rare diseases and oncology. The company’s lead products, Setrusumab and Alvelestat, represent significant advancements in their respective areas. Through its comprehensive approach to clinical development, regulatory strategy, manufacturing, and collaborations, Mereo Biopharma reinforces its commitment to addressing critical healthcare challenges faced by patients with debilitating conditions.